Literature DB >> 32302081

ST-Segment Elevation in Patients with Covid-19 - A Case Series.

Sripal Bangalore1, Atul Sharma1, Alexander Slotwiner1, Leonid Yatskar2, Rafael Harari3, Binita Shah4, Homam Ibrahim3, Gary H Friedman5, Craig Thompson3, Carlos L Alviar6, Hal L Chadow7, Glenn I Fishman3, Harmony R Reynolds3, Norma Keller6, Judith S Hochman3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32302081      PMCID: PMC7182015          DOI: 10.1056/NEJMc2009020

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
To the Editor: Myocardial injury with ST-segment elevation has been observed in patients with coronavirus disease 2019 (Covid-19). Here, we describe our experience in the initial month of the Covid-19 outbreak in New York City. Patients with confirmed Covid-19 who had ST-segment elevation on electrocardiography were included in the study from six New York hospitals. Patients with Covid-19 who had nonobstructive disease on coronary angiography or had normal wall motion on echocardiography in the absence of angiography were presumed to have noncoronary myocardial injury. We identified 18 patients with Covid-19 who had ST-segment elevation indicating potential acute myocardial infarction (Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). The median age of the patients was 63 years, 83% were men, and 33% had chest pain around the time of ST-segment elevation (Table 1). A total of 10 patients (56%) had ST-segment elevation at the time of presentation, and the other 8 patients had development of ST-segment elevation during hospitalization (median, 6 days) (Fig. S2A).
Table 1

Characteristics of 18 Patients with Covid-19 with ST-Segment Elevation on Electrocardiography.*

CharacteristicTotal(N=18)Myocardial Infarction(N=8)NoncoronaryMyocardial Injury(N=10)
Median age (IQR) — yr63 (54–73)60 (56–73)66 (54–73)
Male sex — no. (%)15 (83)7 (88)8 (80)
Race or ethnic group — no. (%)
White4 (22)1 (12)3 (30)
Black2 (11)1 (12)1 (10)
Hispanic9 (50)4 (50)5 (50)
Asian3 (17)2 (25)1 (10)
Risk factor — no. (%)
Hypertension11/17 (65)6/7 (86)5/10 (50)
Diabetes mellitus6/17 (35)3/7 (43)3/10 (30)
Hypercholesterolemia7/17 (41)2/7 (29)5/10 (50)
History of coronary artery disease3/17 (18)0/73/10 (30)
Smoking1/17 (6)1/7 (14)0/10
Chronic obstructive pulmonary disease0/170/70/10
Chronic kidney disease1/17 (6)1/7 (14)0/10
Signs and symptoms around the time of ST-segment elevation — no. (%)
Chest pain6 (33)5 (62)1 (10)
Fever13 (72)6 (75)7 (70)
Cough, shortness of breath, or respiratory distress15 (83)6 (75)9 (90)
Intubation§12 (67)5 (62)7 (70)
Shock7 (39)2 (25)5 (50)
Cardiac arrest2 (11)1 (12)1 (10)
Electrocardiographic findings — no. (%)
Diffuse ST elevations4 (22)04 (40)
Focal elevations14 (78)8 (100)6 (60)
Anterior3 (17)1 (12)2 (20)
Inferior8 (44)4 (50)4 (40)
Lateral9 (50)8 (100)1 (10)
Echocardiographic findings — no. (%)
Normal ejection fraction8/17 (47)1/8 (12)7/9 (78)
Low ejection fraction9/17 (53)7/8 (88)2/9 (22)
Regional wall-motion abnormality6/17 (35)6/8 (75)0/9
Coronary angiography — no. (%)9 (50)6 (75)3 (30)
Obstructive coronary artery disease — no./total no. (%)6/9 (67)6/6 (100)0/3
Percutaneous coronary intervention — no./total no. (%)5/9 (56)5/6 (83)0/3
Findings on radiography of the chest — no. (%)
Opacities in both lungs14 (78)6 (75)8 (80)
Focal opacity1 (6)01 (10)
Normal3 (17)2 (25)1 (10)
Median laboratory values (IQR)
White-cell count — ×10−3/mm38.8 (6.4–11.0)10.0 (7.9–13.5)8.3 (5.8–9.1)
Neutrophils — %85.5 (78.8–88.2)86.1 (73.5–88.6)85.0 (81.5–87.9)
Lymphocytes — %7.4 (6.0–13.1)8.2 (6.7–15.0)7.3 (6.0–11.1)
Peak troponin I — ng/ml44.4 (13.3–80.0)91.0 (65.6–345.0)13.5 (4.8–41.0)
Peak troponin T — ng/ml4.4 (2.2–6.3)6.3 (5.3–7.2)0.02 (0.02–0.02)
d-Dimer — ng/ml858 (652–4541)1909 (682–19,653)858 (541–3580)
Treatment — no. (%)
Fibrinolytic agent1 (6)1 (12)0
Glucocorticoids5 (28)1 (12)4 (40)
Hydroxychloroquine14 (78)5 (62)9 (90)
Azithromycin14 (78)5 (62)9 (90)
Statins11 (61)5 (62)6 (60)
Death in the hospital — no. (%)13 (72)4 (50)9 (90)

Percentages may not total 100 because of rounding. Covid-19 denotes coronavirus disease 2019, and IQR interquartile range.

Race and ethnic group were reported by the patient or were determined by the physician for one patient who was unresponsive.

Risk factors were unknown for one patient, who was found unresponsive at home; investigators were unable to reach any family members for information.

Patients who were intubated had limited history available.

One patient did not have an echocardiogram.

The troponin assay was troponin I in 15 patients and troponin T in 3 patients. The reference value for the troponin I level was 0.06 ng per milliliter or less. The reference value for the troponin T level was 0.01 ng per milliliter or less. The reference value for the d-dimer level was 230 ng per milliliter or less.

Of 14 patients (78%) with focal ST-segment elevation, 5 (36%) had a normal left ventricular ejection fraction, of whom 1 (20%) had a regional wall-motion abnormality; 8 patients (57%) had a reduced left ventricular ejection fraction, of whom 5 (62%) had regional wall-motion abnormalities. (One patient did not have an echocardiogram.) Of the 4 patients (22% of the overall population) with diffuse ST-segment elevation, 3 (75%) had a normal left ventricular ejection fraction and normal wall motion; 1 patient had a left ventricular ejection fraction of 10% with global hypokinesis. A total of 9 patients (50%) underwent coronary angiography; 6 of these patients (67%) had obstructive disease, and 5 (56%) underwent percutaneous coronary intervention (1 after the administration of fibrinolytic agents) (Fig. S3). The relationship among electrocardiographic, echocardiographic, and angiographic findings are summarized in Figure S4. The 8 patients (44%) who received a clinical diagnosis of myocardial infarction had higher median peak troponin and d-dimer levels than the 10 patients (56%) with noncoronary myocardial injury (Fig. S2B and S2C). A total of 13 patients (72%) died in the hospital (4 patients with myocardial infarction and 9 with noncoronary myocardial injury). In this series of patients with Covid-19 who had ST-segment elevation, there was variability in presentation, a high prevalence of nonobstructive disease, and a poor prognosis. Half the patients underwent coronary angiography, of whom two thirds had obstructive disease. Of note, all 18 patients had elevated d-dimer levels. In contrast, in a previous study involving patients who presented with ST-segment elevation myocardial infarction, 64% had normal d-dimer levels.[1] Myocardial injury in patients with Covid-19 could be due to plaque rupture, cytokine storm, hypoxic injury, coronary spasm, microthrombi, or direct endothelial or vascular injury.[2] Myocardial interstitial edema has been shown on magnetic resonance imaging in such patients.[3]
  3 in total

1.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).

Authors:  Riccardo M Inciardi; Laura Lupi; Gregorio Zaccone; Leonardo Italia; Michela Raffo; Daniela Tomasoni; Dario S Cani; Manuel Cerini; Davide Farina; Emanuele Gavazzi; Roberto Maroldi; Marianna Adamo; Enrico Ammirati; Gianfranco Sinagra; Carlo M Lombardi; Marco Metra
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

2.  Myocardial localization of coronavirus in COVID-19 cardiogenic shock.

Authors:  Guido Tavazzi; Carlo Pellegrini; Marco Maurelli; Mirko Belliato; Fabio Sciutti; Andrea Bottazzi; Paola Alessandra Sepe; Tullia Resasco; Rita Camporotondo; Raffaele Bruno; Fausto Baldanti; Stefania Paolucci; Stefano Pelenghi; Giorgio Antonio Iotti; Francesco Mojoli; Eloisa Arbustini
Journal:  Eur J Heart Fail       Date:  2020-04-11       Impact factor: 15.534

3.  D-Dimer Levels Predict Myocardial Injury in ST-Segment Elevation Myocardial Infarction: A Cardiac Magnetic Resonance Imaging Study.

Authors:  Soonuk Choi; Woo Jin Jang; Young Bin Song; Joao A C Lima; Eliseo Guallar; Yeon Hyeon Choe; Jin Kyung Hwang; Eun Kyoung Kim; Jeong Hoon Yang; Joo-Yong Hahn; Seung-Hyuk Choi; Sang-Chol Lee; Sang Hoon Lee; Hyeon-Cheol Gwon
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

  3 in total
  270 in total

Review 1.  Cardiovascular Complications of COVID-19 and Associated Concerns: A Review.

Authors:  Wen-Liang Yu; Han Siong Toh; Chia-Te Liao; Wei-Ting Chang
Journal:  Acta Cardiol Sin       Date:  2021-01       Impact factor: 2.672

2.  Possible association between myocardial infarction with nonobstructed coronary arteries and SARS-CoV-2 infection.

Authors:  Shubham Agarwal; Haitham Al Hashimi; Sanjeev Kumar Agarwal; Usama Albastaki
Journal:  CMAJ       Date:  2020-11-30       Impact factor: 8.262

3.  Cardiac considerations in patients with COVID-19.

Authors:  Oscar Calvillo-Argüelles; Heather J Ross
Journal:  CMAJ       Date:  2020-05-01       Impact factor: 8.262

4.  Gastrointestinal Complications in Critically Ill Patients With COVID-19.

Authors:  Haytham M A Kaafarani; Mohamad El Moheb; John O Hwabejire; Leon Naar; Mathias A Christensen; Kerry Breen; Apostolos Gaitanidis; Osaid Alser; Hassan Mashbari; Brittany Bankhead-Kendall; Ava Mokhtari; Lydia Maurer; Carolijn Kapoen; Kimberly Langeveld; Majed W El Hechi; Jarone Lee; April E Mendoza; Noelle N Saillant; Jonathan Parks; Jason Fawley; David R King; Peter J Fagenholz; George C Velmahos
Journal:  Ann Surg       Date:  2020-05-01       Impact factor: 12.969

5.  Rapid review of COVID-19.

Authors:  Christina Korownyk; G Michael Allan; Nicolas Dugré; Adrienne J Lindblad; James McCormack; Michael R Kolber
Journal:  Can Fam Physician       Date:  2020-06       Impact factor: 3.275

6.  Lessons of the month 3: ST-elevation myocardial infarction and left ventricular thrombus formation: an arterial thrombotic complication of severe COVID-19 infection.

Authors:  Matthew Fenton; Seshnag Siddavaram; Conn Sugihara; Syed Husain
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 7.  Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality.

Authors:  Guoliang Li; Ardan M Saguner; Jiaqi An; Yuye Ning; John D Day; Ligang Ding; Xavier Waintraub; Jie Wang
Journal:  Cardiol J       Date:  2020-08-13       Impact factor: 2.737

8.  Global evaluation of echocardiography in patients with COVID-19.

Authors:  Marc R Dweck; Anda Bularga; Rebecca T Hahn; Rong Bing; Kuan Ken Lee; Andrew R Chapman; Audrey White; Giovanni Di Salvo; Leyla Elif Sade; Keith Pearce; David E Newby; Bogdan A Popescu; Erwan Donal; Bernard Cosyns; Thor Edvardsen; Nicholas L Mills; Kristina Haugaa
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-09-01       Impact factor: 6.875

9.  ST-segment elevation in patients presenting with COVID-19: case series.

Authors:  Mehrdad Saririan; Richard Armstrong; Jon C George; Bartosz Olechowski; Stephen O'Connor; James Brian Byrd; Andrew R Chapman
Journal:  Eur Heart J Case Rep       Date:  2021-02-08

Review 10.  Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?

Authors:  Mallikarjun Patil; Sarojini Singh; John Henderson; Prasanna Krishnamurthy
Journal:  J Cell Physiol       Date:  2020-10-20       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.